… Financial Results Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data … for adRP, data from the Phase 1/2 extension study of sepofarsen, and to start dosing patients with QR-504a for …
… and Financial Results Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; … retinal diseases.” Business Operations and Program Updates Sepofarsen, lead clinical candidate for Leber congenital …
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 … a significant improvement in vision after treatment with sepofarsen in a Phase 1/2 trial. These results strengthen our …
… far with the initiation of both the Phase 2/3 trial for sepofarsen and the proof of concept trial for QR-421a in … to patients.” Corporate Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 In April 2019, the …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr